autologous bone marrow derived cd34+ hsc cells transduced with the lentiviral vector containing a short-hairpin rna targeting bcl11a
Cell therapyexperimental
Clinical trial activity
2 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Feb 13, 2018 (NCT03282656)
Timeline
Indications
Studied for
Mechanism of action
- BCL1Immunity, active
BCL1 immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05353647 | Phase 2 | Jul 12, 2022 | Blood and Marrow Transplant Clinical Trials Network, bluebird bio, California Institute for Regenerative Medicine (CIRM), Harvard University, National Heart, Lung, and Blood Institute (NHLBI) |
| NCT03282656 | Phase 1 | Feb 13, 2018 | Harvard University |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Harvard University | Academic/Hospital | 2 | 2 | 2 | 2018 |
| Blood and Marrow Transplant Clinical Trials Network | Academic/Hospital | 1 | 0 | 1 | 2022 |
| bluebird bio | For profit | 1 | 0 | 1 | 2022 |
| California Institute for Regenerative Medicine (CIRM) | Academic/Hospital | 1 | 0 | 1 | 2022 |
| National Heart, Lung, and Blood Institute (NHLBI) | Government | 1 | 0 | 1 | 2022 |
5 organizations
Page 1 / 1